• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

M Ventures (Merck Ventures B.V., MV)

M Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact the company’s core business areas. From its headquarters in Amsterdam and offices in the US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early stage investing and company creation including the creation of spin-offs to leverage the company’s science and technology base. *

 

	Start	2016-06-08 renamed
	Group	Merck (DE) (Group)
	Predecessor	MS Ventures (Merck Serono Ventures)
	Industry	venture capital
	Industry 2	BIOTECH
	Person	Bulthuis, Roel (Inkef Capital 201811– Managing Director + Head Heathcare before Merck M Ventures + Fortis Bank + Devgen)
	Region	Amsterdam
	Country	Netherlands
	Street	84a Gustav Mahlerplein Ito Toren, 13th floor
	City	1082 MA Amsterdam
		Address record changed: 2016-11-08
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	300,000,000 (capital, committed 2016-06-08)
		* Document for �About Section�: FoRx Therapeutics AG. (4/22/20). "Press Release: FoRx Therapeutics AG Raises EUR 10 Million Seed Round". Basel.
		Record changed: 2020-09-26

Advertisement

More documents for Merck (DE) (Group)

• [1] Merck KGaA. (11/9/20). "Press Release: Merck Announces Out-licensing Agreement for Investigational Atacicept with Vera Therapeutics [Not intended for UK and US based media]". Darmstadt....
• [2] Merck KGaA. (10/12/20). "Press Release: Merck Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio USA". Darmstadt....
• [3] Precigen, Inc.. (10/9/20). "Press Release: Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note". Germantown, MD....
• [4] Merck KGaA. (10/8/20). "Press Release: Merck Celebrates Topping-Out Ceremony for New Membrane Production Plant". Darmstadt....
• [5] Merck KGaA. (10/6/20). "Press Release: Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis [Not intended for UK and US based media]". Darmstadt....
• [6] Merck KGaA. (9/29/20). "Press Release: Press Release as a Result of the Ad-hoc Announcement of September 29, 2020". Darmstadt....
• [7] Merck KGaA. (9/28/20). "Press Release: Stefan Oschmann to Hand Over Chair of Executive Board to Belén Garijo in 2021". Darmstadt....
• [8] Ipsen S.A.. (9/25/20). "Press Release: Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer". Paris....
• [9] Amadeus Capital Partners. (9/15/20). "Press Release: Amadeus Appoints New Partners Edward Kliphuis and Kai Schmitz". London & Bogotá....
• [10] Merck KGaA. (9/9/20). "Press Release: Merck Announces € 59 Million Antibody-Drug Conjugate Manufacturing Expansion". Darmstadt....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.